BridgeBio Gets US Approval for Heart Drug to Compete with Pfizer
BridgeBio Pharma Inc. gained US approval for a drug to treat a progressive and deadly form of heart disease, paving the way ...
How Pfizer is trying to make U.S. healthcare easier to navigate
The pharma leader is betting that streamlined services may be a shot in the arm for Americans seeking care with its ...
Pfizer Stock Drops 10% In November On News Of Kennedy's HHS Nomination
Pfizer shares are trading lower by 10% in November. President-elect Donald Trump last week announced his intention to nominate Robert F. Kennedy Jr. to lead the HHS.
FiercePharma22h
As other Big Pharmas face local headwinds, Pfizer doubles down on China commitment with Zai Lab antimicrobial marketing pact
For Big Pharma, recent headlines out of China suggest multinational drugmakers are facing their share of challenges in the ...
FierceBiotech23h
Chutes & Ladders—Pfizer replaces retiring CSO with cancer chief
Pfizer has found a successor for retiring Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the ...
BioSpace2d
Pfizer Shakes Up C-Suite, Elevating Cancer Chief Boshoff to CSO
Chris Boshoff will take over as Pfizer’s next chief scientific officer as of January 1, replacing Mikael Dolsten who led the ...
Pfizer cannot recoup $75 million from SEC insider trading settlement, judge rules
A federal judge on Tuesday rejected Pfizer's bid to recoup about $75.2 million left over from a U.S. Securities and Exchange ...
FierceBiotech2d
Pfizer plucks internal candidate to replace R&D head Dolsten, triggering series of leadership shakeups
Pfizer has found a successor for Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the company’s own ...
The Motley Fool on MSN3d
Is It Time to Sell Eli Lilly and Pfizer Stocks?
Lilly and Pfizer stocks have sold off sharply in recent weeks. Both drugmakers have had some bad news that caused their ...
BioWorld1d
Zai Lab, Pfizer team up to widen China access to antibacterial Xacduro
Zai Lab and Pfizer Inc. are teaming up in China to fight the deadly carbapenem-resistant Acinetobacter baumannii (CRAB) infection with novel antibacterial drug Xacduro (sulbactam-durlobactam).